Dr. David Shapiro is the founder, president, and CEO of Integrated Quality Resources (IQR), a consulting company focused on development stage biopharmaceutical companies. Previously, he served as chief medical officer and executive vice president for research and development at Intercept Pharmaceuticals.
Dr. Shapiro’s clinical development experience spans over 30 years in the pharmaceutical industry. He has been in his role with IQR since 1998, and he spent 12 years with Intercept from 2007 to 2019. Additionally, he served as CMO and executive vice president, medical affairs for Idun Pharmaceuticals (later acquired by Pfizer) from 2000 to 2005. Prior to Idun, he served as president of the Scripps Medical Research Center at Scripps Clinic from 1995 to 1998.
Previously, he held research positions at Gensia Pharmaceuticals and Merck Research Laboratories.
Dr. Shapiro has authored over 20 peer-reviewed publications, and he has also organized and chaired multiple conferences focused on improving product development. He is an elected fellow of London’s Royal College of Physicians and the Faculty of Pharmaceutical Physicians of the United Kingdom. He currently serves on the board of directors of Galecto, Inc., a clinical stage biotechnology company focused on fibrosis and cancer treatments.
Dr. Shapiro earned his M.D. from Dundee University Medical School, and he completed his internal medicine residency program through Oxford University Teaching Hospitals.
What is David Shapiro's net worth?
The estimated net worth of David Shapiro is at least $262,542.00 as of February 19th, 2021. Dr. Shapiro owns 13,818 shares of Intercept Pharmaceuticals stock worth more than $262,542 as of March 28th. This net worth estimate does not reflect any other investments that Dr. Shapiro may own. Learn More about David Shapiro's net worth.
How do I contact David Shapiro?
Has David Shapiro been buying or selling shares of Intercept Pharmaceuticals?
David Shapiro has not been actively trading shares of Intercept Pharmaceuticals within the last three months. Most recently, David Shapiro sold 2,000 shares of the business's stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $86.28, for a transaction totalling $172,560.00. Following the completion of the sale, the insider now directly owns 41,499 shares of the company's stock, valued at $3,580,533.72. Learn More on David Shapiro's trading history.
Who are Intercept Pharmaceuticals' active insiders?